222 related articles for article (PubMed ID: 9145976)
1. Role of prostate-specific antigen velocity in prediction of final pathologic stage in men with localized prostate cancer.
Thiel R; Pearson JD; Epstein JI; Walsh PC; Carter HB
Urology; 1997 May; 49(5):716-20. PubMed ID: 9145976
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
3. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
4. PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness.
Loeb S; Sutherland DE; D'Amico AV; Roehl KA; Catalona WJ
Urology; 2008 Nov; 72(5):1116-20; discussion 1120. PubMed ID: 18571700
[TBL] [Abstract][Full Text] [Related]
5. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
[TBL] [Abstract][Full Text] [Related]
6. Relapse after radical prostatectomy correlates with preoperative PSA velocity and tumor volume: results from a screening population.
Berger AP; Deibl M; Strasak A; Bektic J; Pelzer A; Steiner H; Spranger R; Fritsche G; Bartsch G; Horninger W
Urology; 2006 Nov; 68(5):1067-71. PubMed ID: 17095070
[TBL] [Abstract][Full Text] [Related]
7. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
[TBL] [Abstract][Full Text] [Related]
8. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
[TBL] [Abstract][Full Text] [Related]
9. Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
Aus G; Becker C; Lilja H; Khatami A; Pihl CG; Hugosson J
Scand J Urol Nephrol; 2003; 37(6):466-70. PubMed ID: 14675918
[TBL] [Abstract][Full Text] [Related]
10. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
[TBL] [Abstract][Full Text] [Related]
11. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and Gleason score to predict positive surgical margins.
Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
Urology; 2004 Sep; 64(3):516-21. PubMed ID: 15351582
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.
Chun FK; Briganti A; Gallina A; Hutterer GC; Shariat SF; Antebie E; Walz J; Roehrborn CG; Salonia A; Rigatti P; Saad F; Huland H; Montorsi F; Graefen M; Karakiewicz PI
Eur Urol; 2007 Oct; 52(4):1067-74. PubMed ID: 17383807
[TBL] [Abstract][Full Text] [Related]
13. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease.
Miyake H; Sakai I; Harada K; Hara I; Eto H
Int J Urol; 2005 Mar; 12(3):270-4. PubMed ID: 15828954
[TBL] [Abstract][Full Text] [Related]
14. Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis.
Zhu H; Roehl KA; Antenor JA; Catalona WJ
Urology; 2005 Sep; 66(3):547-51. PubMed ID: 16140075
[TBL] [Abstract][Full Text] [Related]
15. Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease.
Freedland SJ; Mangold LA; Epstein JI; Partin AW
Urology; 2004 May; 63(5):887-91. PubMed ID: 15134972
[TBL] [Abstract][Full Text] [Related]
16. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
[TBL] [Abstract][Full Text] [Related]
17. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.
Graefen M; Karakiewicz PI; Cagiannos I; Hammerer PG; Haese A; Palisaar J; Huland E; Scardino PT; Kattan MW; Huland H
J Urol; 2002 Mar; 167(3):1306-9. PubMed ID: 11832719
[TBL] [Abstract][Full Text] [Related]
18. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.
D'Amico AV; Chen MH; Roehl KA; Catalona WJ
N Engl J Med; 2004 Jul; 351(2):125-35. PubMed ID: 15247353
[TBL] [Abstract][Full Text] [Related]
19. An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less.
Zlotta AR; Remzi M; Snow PB; Schulman CC; Marberger M; Djavan B
J Urol; 2003 May; 169(5):1724-8. PubMed ID: 12686818
[TBL] [Abstract][Full Text] [Related]
20. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
